These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 25339045)
1. Association between cigarette smoking and RASSF1A gene promoter hypermethylation in lung cancer patients: a meta- analysis. Wu XM; Chen Y; Shao Y; Zhou XL; Tang WR Asian Pac J Cancer Prev; 2014; 15(19):8451-4. PubMed ID: 25339045 [TBL] [Abstract][Full Text] [Related]
2. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Kim DH; Kim JS; Ji YI; Shim YM; Kim H; Han J; Park J Cancer Res; 2003 Jul; 63(13):3743-6. PubMed ID: 12839968 [TBL] [Abstract][Full Text] [Related]
3. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. Liu Y; Gao W; Siegfried JM; Weissfeld JL; Luketich JD; Keohavong P BMC Cancer; 2007 May; 7():74. PubMed ID: 17477876 [TBL] [Abstract][Full Text] [Related]
4. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916 [TBL] [Abstract][Full Text] [Related]
5. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data. Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171 [TBL] [Abstract][Full Text] [Related]
6. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Divine KK; Pulling LC; Marron-Terada PG; Liechty KC; Kang T; Schwartz AG; Bocklage TJ; Coons TA; Gilliland FD; Belinsky SA Int J Cancer; 2005 Apr; 114(3):400-5. PubMed ID: 15578700 [TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence. Marsit CJ; Kim DH; Liu M; Hinds PW; Wiencke JK; Nelson HH; Kelsey KT Int J Cancer; 2005 Mar; 114(2):219-23. PubMed ID: 15540210 [TBL] [Abstract][Full Text] [Related]
8. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis. Wen G; Wang H; Zhong Z Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221 [TBL] [Abstract][Full Text] [Related]
9. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis. Huang YZ; Wu W; Wu K; Xu XN; Tang WR Asian Pac J Cancer Prev; 2014; 15(23):10325-8. PubMed ID: 25556469 [TBL] [Abstract][Full Text] [Related]
10. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Cirincione R; Lintas C; Conte D; Mariani L; Roz L; Vignola AM; Pastorino U; Sozzi G Int J Cancer; 2006 Mar; 118(5):1248-53. PubMed ID: 16152615 [TBL] [Abstract][Full Text] [Related]
11. Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Wang J; Lee JJ; Wang L; Liu DD; Lu C; Fan YH; Hong WK; Mao L Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6119-25. PubMed ID: 15447998 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic Role of RASSF1A and p16INK4a Promoter Gene Hypermethylation in Serum DNA of Lung Cancer Patients: Clinicopathological Significance. El-Sherif WT; Sayed SK; Galal SH; Makhlouf HA; Hassan AT; Yousef HA Egypt J Immunol; 2016 Jun; 23(2):1-16. PubMed ID: 28502129 [TBL] [Abstract][Full Text] [Related]
14. Aberrant Methylation of RASSF1A gene Contribute to the Risk of Renal Cell Carcinoma: a Meta-Analysis. Yu GS; Lai CY; Xu Y; Bu CF; Su ZX Asian Pac J Cancer Prev; 2015; 16(11):4665-9. PubMed ID: 26107221 [TBL] [Abstract][Full Text] [Related]
15. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma. Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383 [TBL] [Abstract][Full Text] [Related]
16. Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance. Lee SM; Lee WK; Kim DS; Park JY Mol Med Rep; 2012 Jan; 5(1):239-44. PubMed ID: 21971684 [TBL] [Abstract][Full Text] [Related]
17. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069 [TBL] [Abstract][Full Text] [Related]
18. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma. Saelee P; Wongkham S; Chariyalertsak S; Petmitr S; Chuensumran U Asian Pac J Cancer Prev; 2010; 11(6):1677-81. PubMed ID: 21338215 [TBL] [Abstract][Full Text] [Related]
19. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer]. Wei H; Fang N; Guo L; Wu Z; Zhou Q Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):443-50. PubMed ID: 26182870 [TBL] [Abstract][Full Text] [Related]
20. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Wang J; Wang B; Chen X; Bi J Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]